This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
LogicBio Therapeutics Future Growth
Future criteria checks 0/6
Key information
n/a
Earnings growth rate
-1.2%
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | -132.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | N/A | N/A | -28 | N/A | 1 |
| 12/31/2022 | 10 | N/A | -27 | N/A | 2 |
| 9/30/2022 | 11 | -27 | -25 | -25 | N/A |
| 6/30/2022 | 10 | -31 | -29 | -28 | N/A |
| 3/31/2022 | 8 | -36 | -22 | -21 | N/A |
| 12/31/2021 | 5 | -40 | -20 | -19 | N/A |
| 9/30/2021 | 4 | -38 | -22 | -21 | N/A |
| 6/30/2021 | 3 | -36 | -17 | -17 | N/A |
| 3/31/2021 | 3 | -33 | -30 | -29 | N/A |
| 12/31/2020 | 3 | -33 | -29 | -29 | N/A |
| 9/30/2020 | 3 | -37 | -34 | -33 | N/A |
| 6/30/2020 | 2 | -40 | -39 | -38 | N/A |
| 3/31/2020 | 1 | -42 | -39 | -38 | N/A |
| 12/31/2019 | N/A | -40 | -40 | -39 | N/A |
| 9/30/2019 | N/A | -32 | -33 | -32 | N/A |
| 6/30/2019 | N/A | -29 | -27 | -26 | N/A |
| 3/31/2019 | N/A | -23 | -21 | -20 | N/A |
| 12/31/2018 | N/A | -18 | -16 | -15 | N/A |
| 9/30/2018 | N/A | -18 | -14 | -13 | N/A |
| 6/30/2018 | N/A | -11 | -11 | -11 | N/A |
| 3/31/2018 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2017 | N/A | -8 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if LOGC's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if LOGC's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if LOGC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LOGC's revenue is expected to decline over the next 3 years (-132.5% per year).
High Growth Revenue: LOGC's revenue is forecast to decline over the next 3 years (-132.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LOGC's Return on Equity is forecast to be high in 3 years time